- Enteris, KeyBioscience to Develop Solution for Metabolic Disorders
Enteris BioPharma Enters into Agreement with Nordic Bioscience’s KeyBioscience to Develop Orally Delivered Metabolic Peptide
Enteris to lead the formulation and clinical manufacturing of Peptelligence™-enabled compounds targeting multiple, high-value medical indications
Boonton, NJ – January 25, 2017 – Enteris BioPharma, Inc., a biotechnology company developing innovative drug products built around its proprietary delivery technologies, today announced the initiation of a clinical manufacturing services agreement with KeyBioscience AG, a wholly-owned subsidiary of Nordic Bioscience, whereby Enteris will leverage its proprietary Peptelligence™ platform to advance the development of a proprietary metabolic peptide for the treatment of various indications, including diabetes, obesity, and other metabolic disorders.
Under the terms of the agreement, Enteris BioPharma will leverage its Peptelligence™ platform to manufacture and characterize three oral tablet prototypes of KeyBioscience’s metabolic peptide, as well as become the exclusive provider of finished product for use in pre-clinical and proof-of-concept clinical trial research.
Joel Tune, Chief Executive Officer and Executive Chairman of Enteris BioPharma, commented, “This agreement with Nordic Bioscience showcases the value of our Peptelligence™ platform to develop and enable the oral delivery of promising peptide and small molecule therapeutics. Additionally, it highlights our unique ability to partner with global pharmaceutical companies to develop drug products that address significant patient care and market opportunities. We are truly excited to be working with Key Bioscience on this new class of compounds.”
Morten Karsdal, Chief Executive Officer of Nordic Bioscience, remarked, “The ability to deliver our proprietary DACRA peptides orally offers KeyBioscience the potential to bring to market a new therapeutic choice for the treatment of metabolic disorders, which is a significant market opportunity. An oral delivery using Enteris’s Peptelligence™ platform and manufacturing capabilities will be a value driver and a key to success. We look forward to progress with an oral formulation of our DACRA peptides into clinical trials and potential commercialization.”
About KeyBioscience and Nordic Bioscience
KeyBioscience develops and hold all rights to DACRA peptides for various metabolic and cartilage related diseases. KeyBioscience is a fully owned subsidiary of Nordic Bioscience, a global drug development organization headquartered in Copenhagen, Denmark. Nordic Bioscience is engaged in clinical research and innovative biomarker research focusing on connective tissue diseases. The capabilities and experience with research and development place Nordic Bioscience in a unique position to develop advanced specialized protocols to conduct innovative clinical studies from Phase 1 to Phase 3. Using a data-driven approach, Nordic Bioscience has a long history of applying novel technologies in translational and biomarker science promoting precision medicine, particularly within rheumatology.
For additional information please visit the company’s website at http://nordicbioscience.com.
About Enteris BioPharma
Enteris BioPharma, Inc. is a privately held, New Jersey-based biotechnology company offering innovative formulation solutions built around its proprietary drug delivery technologies. Enteris’ proprietary oral delivery technology – Peptelligence™ – has been the subject of numerous feasibility studies and active development programs, several of which are in late stage clinical development. Enteris BioPharma’s most advanced internal product candidate, Ovarest™, an oral peptide for endometriosis will begin Phase 2A trials in the next quarter.
For more information on Enteris BioPharma and its proprietary oral delivery technology, please visit http://www.EnterisBioPharma.com.
|For Enteris BioPharma:||Enteris Media Relations:|
|Brian Zietsman, President & CFO|
|Jason Rando / Amy Wheeler|
Tiberend Strategic Advisors, Inc.